Clinical Trials Logo

Glioma clinical trials

View clinical trials related to Glioma.

Filter by:

NCT ID: NCT01567202 Recruiting - Neoplasms Clinical Trials

Study of DC Vaccination Against Glioblastoma

Start date: March 2012
Phase: Phase 2
Study type: Interventional

This is a Phase II study in a single center to determine the efficacy of autologous dendritic cells (DCs) loaded with autogeneic glioma stem-like cells (A2B5+) administered as a vaccination in adults with glioblastoma multiforme (primary or secondary).

NCT ID: NCT01525459 Recruiting - Glioma Clinical Trials

Gene Expression, Immunological Status and Metabolome in Glioma Patients

Start date: December 2010
Phase: N/A
Study type: Observational

Study on glioma patients treated with brain surgery is focusing on the analysis of their transcriptome expression profile measured in two immune cell populations, CD4+ T cells and CD56+ NK cells. The results of analysis will be compared to the reference data of healthy population. Furthermore, the metabolomic and immunological status will also be monitored and compared to healthy group reference data, before and after the surgery*. With comparative crossomics analysis the investigators intend to possibly identify new diagnostic and prognostic biological markers for the relapse of the disease. The results are expected to convey a deeper insight into pathophysiology of the glioma as well as into the mechanisms of the current surgical therapy. * The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB (Gruden et al. 2012).

NCT ID: NCT01386450 Recruiting - Low Grade Glioma Clinical Trials

AZD6244 in Children With Low-Grade Gliomas

Start date: June 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Background: - AZD6244 is an experimental drug designed to prevent tumor growth and shrink existing tumors. It has been studied in adults with cancer, but it has not been studied in children with cancer. Researchers want to see if AZD6244 is a safe and effective treatment for older children and young adults who have gliomas (brain tumors) that have not responded to standard treatments. Objectives: - To test the safety and effectiveness of AZD6244 in older children and young adults who have gliomas that have not responded to standard treatments. Eligibility: - People between 12 and 21 years of age who have gliomas that have not responded to standard treatments. Design: - Participants will be screened with a medical history and physical exam. They will also have blood tests and tumor imaging studies. Those in the study may also have their spinal fluid tested to see whether the cancer has spread to other parts of the nervous system. - Participants will take AZD6244 as a capsule. It must be swallowed whole on an empty stomach twice a day for 28 days. Those in the study will have up to 13 cycles (4 weeks each) of treatment (1 year). - Participants will keep a diary to record doses taken and any side effects of the treatment. - Participants will have frequent blood tests and imaging studies.

NCT ID: NCT01106794 Recruiting - Clinical trials for Diffuse Intrinsic Pontine Glioma

Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma

Start date: April 2010
Phase:
Study type: Observational

The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular abnormalities of this tumor.

NCT ID: NCT00887146 Recruiting - Clinical trials for Brain and Central Nervous System Tumors

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Start date: September 2009
Phase: Phase 3
Study type: Interventional

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.

NCT ID: NCT00870129 Recruiting - Glioma Clinical Trials

Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

Start date: March 2009
Phase: N/A
Study type: Interventional

The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. WeThe reserchers are doing this study to see whether this advanced imaging is a safe treatment that causes few or mild side effects in people with brain tumors.

NCT ID: NCT00813787 Recruiting - Glioma Clinical Trials

Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components

Start date: February 2009
Phase: N/A
Study type: Observational

The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.

NCT ID: NCT00686387 Recruiting - Glioma Clinical Trials

Establishment of a Brain and Spinal Tumor Tissue Bank

Start date: May 2008
Phase: N/A
Study type: Observational

The purpose of this study is to establish a Brain and Spinal Tumor Tissue/Specimen repository to serve as a resource for current and future scientific studies.

NCT ID: NCT00660621 Recruiting - Glioma Clinical Trials

A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

KARE004
Start date: April 2008
Phase: Phase 2
Study type: Interventional

To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in subjects undergoing initial surgery for newly-diagnosed high grade glioma.

NCT ID: NCT00454935 Recruiting - Epilepsy Clinical Trials

Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy

Start date: April 2007
Phase: Phase 4
Study type: Observational

The purpose of this study is to investigate the correlation of SV2A expression in surgically removed tumour and tumour-surrounding tissue of glioma patients suffering from epilepsy with their clinical response to levetiracetam.